Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies-Reference-Cited by-同舟云学术

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies

Published:2015-06-01 Issue:3 Volume:80 Page:342-350
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Greenblatt David J.¹,Harmatz Jerold S.¹

Affiliation:

1. From the Program in Pharmacology and Experimental Therapeutics; Tufts University School of Medicine and Sackler School of Graduate Biomedical Sciences; Boston MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12668/fullpdf

Reference114 articles.

1. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems 2013

2. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole 2013

3. FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects 2013

4. Liver injury associated with ketoconazole: Review of the published evidence;Greenblatt;J Clin Pharmacol,2014

5. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database;Raschi;World Journal of Hepatology,2014

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy;Xenobiotica;2024-08-28

2. Pharmacokinetic analysis of antiviral drug ritonavir across the blood–brain barrier and its interaction with Scutellaria baicalensis using multisite microdialysis in rats;Journal of Pharmaceutical and Biomedical Analysis;2024-08

3. Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants;Clinical Pharmacology in Drug Development;2024-04-16

4. Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants;Clinical Pharmacology in Drug Development;2024-02-29

5. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib;Clinical Pharmacology in Drug Development;2024-02-29